GlassScriptPhysician profile
Kenneth A Grossman
NPI 1427012533
$9,121.47
in general payments reported to CMS, 2019-2025
35 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what 76% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $291 · 2021: $1,144 · 2022: $1,610 · 2023: $1,647 · 2024: $1,961 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,086 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,086.38 |
| Education | $354.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,798.54 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $1,685.53 | 2019-2025 | |
| Leo Pharma INC. | $552.87 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $453.58 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $436.46 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $417.60 | 2021-2025 | |
| Pfizer INC. | $389.47 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $366.47 | 2023-2025 | Zoryve |
| Amgen INC. | $364.96 | 2020-2025 | Otezla, Enbrel, Otezla |
| Sun Pharmaceutical Industries INC. | $283.17 | 2019-2025 | Ilumya, Winlevi |
| Genzyme Corporation | $276.89 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $261.22 | 2019-2025 | Cabtreo, Arazlo, Siliq |
| Ucb, INC. | $258.72 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $256.64 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Almirall LLC | $176.50 | 2021-2025 | Seysara |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $154.13 | 2019-2025 | |
| Revance Therapeutics, INC. | $138.78 | 2025 | Daxxify |
| Incyte Corporation | $136.76 | 2023 | Opzelura |
| Janssen Scientific Affairs, LLC | $124.98 | 2021 | |
| Epi Health, LLC | $97.82 | 2019-2022 | |
| Organon LLC | $89.97 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $76.86 | 2023-2024 | Sotyktu |
| Helsinn Therapeutics (U.S.), INC. | $66.49 | 2021-2023 | Valchlor |
| Dermavant Sciences, INC. | $51.75 | 2023-2024 | Vtama |
| Journey Medical Corporation | $51.09 | 2022 | |
| Verrica Pharmaceuticals INC. | $28.56 | 2024 | Ycanth |
| Hill Dermaceuticals, INC. | $22.98 | 2023 | Tolak |
| Krystal Biotech INC | $16.57 | 2025 | Vyjuvek |
| Botanix Sb INC | $15.28 | 2025 | Sofdra |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Encore Dermatology INC. | $12.06 | 2019 | |
| Sebela Pharmaceuticals INC. | $11.89 | 2022 | |
| Celgene Corporation | $11.72 | 2019 | |
| Kyowa Kirin, INC. | $11.38 | 2020 | |
| Biofrontera INC. | $10.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Grossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.